Figure 1

Distribution of epidermal growth factor receptor (EGFR) mutant-allele copy number in plasma samples before osimertinib (pretreatment), 1 month after its administration, and at progressive disease to its treatment, according to the EGFR mutation status of exon 19 deletion (A), exon 21 L858R (B), T790M (C), and C797S (D).